Deslanoside
As of the edition of 20 October 2026, Deslanoside is a small molecule: marketed, first approved in 1982 (US); acts on ATP1A1, ATP1A2 and ATP1A3 and 1 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1982
- Kind
- Small molecule
- Brand name
- Cedilanid-D
- First approved
- 1 January 1982 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Novartis
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Targets
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Applicant |